The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $15.50

Today's change+0.50 +3.33%
Updated January 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $15.50

Today's change+0.50 +3.33%
Updated January 17 4:00 PM EST. Delayed by at least 15 minutes.

Momenta Pharmaceuticals Inc crosses above 200-day moving average

Momenta Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$0.50 or 3.33% to (U.S.)$15.50 and crossing above its 200-day moving average. Over the last five days, shares have gained 11.51% and 3.33% over the last 52 weeks. However, this lagged the 23.58%. gain in the S&P 500.

Key company metrics

  • Open(U.S.) $15.20
  • Previous close(U.S.) $15.00
  • High(U.S.) $15.65
  • Low(U.S.) $14.90
  • Bid / Ask(U.S.) $13.75 / (U.S.) $17.80
  • YTD % change+11.11%
  • Volume980,008
  • Average volume (10-day)1,072,517
  • Average volume (1-month)823,063
  • Average volume (3-month)850,266
  • 52-week range(U.S.) $11.85 to (U.S.) $19.90
  • Beta1.68
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.80
Updated January 17 4:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.17%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue24242734
Total other revenue--------
Total revenue24242734
Gross profit--------
Total cost of revenue--------
Total operating expense59625945
Selling / general / administrative21232318
Research & development38393626
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-35-38-33-10
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-33-37-3242
Income after tax-33-37-3242
Income tax, total--------
Net income-33-37-3242
Total adjustments to net income--------
Net income before extra. items-33-37-3242
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-33-37-3242
Inc. avail. to common incl. extra. items-33-37-3242
Diluted net income-33-37-3242
Dilution adjustment--------
Diluted weighted average shares75737069
Diluted EPS excluding extraordinary itemsvalue per share-0.44-0.50-0.460.60
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.44-0.50-0.460.60